Assessment of efficacy of Anti-IgE (Omalizumab) therapy in patients with severe allergic asthma in a tertiary care hospital of Eastern India

Ghosh S.¹, Gayen P.², Mandal A.³*, Bandyopadhyay R.⁴

DOI: https://doi.org/10.17511/ijmrr.2019.i03.10

¹ Saswata Ghosh, Assistant Professor, Department of Chest Medicine, Malda Medical College and Hospital, Malda, West Bengal, India.
² Prosenjit Gayen, Assistant Professor, Department of Pathology, Malda Medical College and Hospital, Malda, West Bengal, India.
³* Animesh Mandal, Assistant Professor, Department of Chest Medicine, Malda Medical College and Hospital, Malda, West Bengal, India.
⁴ Ramtanu Bandyopadhyay, Professor, Department of General Medicine, Malda Medical College and Hospital, Malda, West Bengal, India.

Introduction: Immunoglobulin E dependent mechanisms play an important role in the development of airway inflammation in allergic asthma. Atopic patients with severe asthma frequently have poorly controlled disease. Many have poor asthma control despite intensive treatment. Severe allergic asthma patients frequently treated with oral corticosteroids and therefore may develop serious side-effects. Anti-IgE antibody had been used in severe persistent allergic asthma in Western countries. However, its long-term efficacy in patients in India has not been reported. Objective: To assess the efficacy of anti IgE therapy in patients with severe allergic asthma. Method: 30 (16 male and 14 female) patients, with mean age of 49 having severe persistent allergic asthma, with recurrent exacerbations and on oral/IV steroids, received Omalizumab 150mg/300mg/450 mg for 1 year. Total dose of oral Steroids, use of rescue medications, changes in lung function (FEV1) were recorded at the baseline, 16 weeks & at end of the treatment (52 weeks) and then analyzed. Results: Significant reduction observed in total oral steroid use at 16 week & at 52 weeks. -10.5mg (p<0.003) & 22.5mg respectively. Use of rescue medications decreased by -7.90 puffs (p <0.001) at 16 weeks and by -13.67 puffs (13.67 (p -<0.001) at 52 weeks. Improvements in lung Function (FEV1) observed with a tune of 700 ml from Baseline after 52 weeks therapy. Conclusion: Use of anti-IgE antibody for 1 year is well tolerated and led to an overall significant improvement in patients with severe persistent allergic asthma.

Keywords: Severe allergic asthma, Anti IgE therapy, Omalizumab
Introduction

Asthma remains a major public health problem and a significant proportion of patients have severe, persistent disease that is refractory to continuous treatment, even with a combination of high-dose inhaled corticosteroids and long-acting b2-agonists. Maintenance oral corticosteroids (OCS) are frequently administered to achieve control in those patients [1]. However, regular OCS use is associated with significant systemic side effects including cataracts, high blood sugar among non-diabetics, osteoporosis, acne, weight gain, sleep and mood disturbances [2].

Omalizumab is a recombinant, DNA-derived, humanized monoclonal antibody that selectively binds to human IgE. This prevents the interaction of IgE to the high-affinity receptors on basophils and mast cells, thus interrupting the inflammatory cascade involved in the pathogenesis of allergic asthma. Several studies have demonstrated the therapeutic efficacy and safety of omalizumab in asthmatic patients and have found a reduced annual rate of clinically significant asthma exacerbations, systemic requirements of corticosteroids, emergency department (ED) visits, and overall symptoms [1,3,4,5].

This therapy has been incorporated into the current guidelines for the treatment of asthma. Current GINA guidelines recommend use of omalizumab as a step 5 treatment, in patients who remain symptomatic despite optimum treatment [6]. The study was undertaken to investigate the clinical effects of omalizumab (Anti IgE) therapy in a population of Indian patients with severe, persistent, allergic asthma.

According to American Academy of Allergy, Asthma and Immunology, Allergic asthma is the most common form of asthma. Many of the symptoms of allergic and non-allergic asthma are the same. However, allergic asthma is triggered by inhaling allergens. An allergen is a typically harmless substance such as dust mites, pet dander, pollen or mold. If you are allergic to a substance, this allergen triggers a response starting in the immune system.

Through a complex reaction, these allergens then cause the passages in the airways of the lungs to become inflamed and swollen. This results in coughing, wheezing and other asthma symptoms.

The definition of severe asthma (according to ERS/ATS 2014) is that group of patients who needs treatment with high-dose ICS + at least one additional controller (LABA, montelukast, or theophylline) or oral corticosteroids >6 months/year.

Objective: To assess the efficacy of anti IgE therapy in patients with severe allergic asthma.

Methods

01. a) Study Type: Single centre, 52-week, observational study conducted at Medical College and Hospital, Malda in Eastern India.
   Place of study: OPD, Department of Chest Medicine, Malda Medical College & Hospital, Malda.

02. b) Sample Size: Total 30 patients with severe allergic asthma were enrolled.

03. c) Sampling Technique: Consecutive non-probability technique used.

04. d) Inclusion Criteria: Clinical diagnosis of severe asthma, positive allergy test results for at least 1 perennial aeroallergen, IgE level 30 to 1500 IU/ml, regular/occasional requirement of systemic steroid treatment (IV or oral), and frequent exacerbations requiring emergency visit/hospitalization.

05. e) Exclusion Criteria: 1) Mild to moderate asthma 2) Severe allergic asthma but with comorbidities 3) Patients unwilling to join the study.

06. f) Study Procedure: Study commenced after obtaining permission from Institutional Ethical Committee and written informed consent from patients. Data were obtained from patients diagnosed with severe allergic asthma, and received omalizumab. Omalizumab was administered according to a dosing table nomogram incorporating the patients’ bodyweight and baseline IgE levels.

Data Analysis: Data on the following parameters were collected at Baseline (prior to commencing omalizumab therapy), 16 weeks and 52 weeks after omalizumab initiation:

- OCS (Oral Corticosteroid) dose
- ACT (Asthma Control Test) score
- Use of rescue medication, and
- Lung function (FEV1)
Change in ICS dose, LABA dose, and status of asthma control (mild, moderate, or severe) were also recorded.

Summary statistics describing change from baseline in OCS dose, ACT score, rescue medication use and change in FEV1 were calculated for all patients receiving omalizumab.

**Results**

A total of 30 patients (53.3% male, 46.7% female) who were receiving omalizumab were included in this study.

### Table 1: Demographic profile of patients.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Patients (n=30)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age, years</td>
<td>53.3</td>
</tr>
<tr>
<td>Female, n (%)</td>
<td>14(46.7%)</td>
</tr>
<tr>
<td>Mean duration of allergic asthma, years</td>
<td>28.6 years</td>
</tr>
<tr>
<td>Positive skin-prick test/RAST for perennial aeroallergens, (%)</td>
<td>95.6%</td>
</tr>
<tr>
<td>History of seasonal allergy, (%)</td>
<td>67.3%</td>
</tr>
<tr>
<td>Smoking history, (%)</td>
<td></td>
</tr>
<tr>
<td>Never smoked</td>
<td>78.6%</td>
</tr>
<tr>
<td>Ex-smoker</td>
<td>15.8%</td>
</tr>
<tr>
<td>Current smoker</td>
<td>5.6%</td>
</tr>
<tr>
<td>Asthma control/severity (investigator assessment), (%)</td>
<td></td>
</tr>
<tr>
<td>Controlled</td>
<td>0</td>
</tr>
<tr>
<td>Partly controlled/Moderate</td>
<td>30% (9 patients)</td>
</tr>
<tr>
<td>Uncontrolled/severe</td>
<td>70% (21 patients)</td>
</tr>
</tbody>
</table>

Classified by severity, 70% of the patients have severe asthma, and 30% had moderate (partially controlled) asthma. No patients with mild (well-controlled) asthma were included in the study. The key baseline characteristics are listed in the table above:

**OCS (Oral Corticosteroid) dosing:** The mean total daily OCS dose reduction at 16 week & at 52 weeks from Baseline was 10.5mg (p<0.003) & 22.5mg, respectively. The proportion of patients receiving OCS was lower at Week 16 (40%) and week 52 (23.3%) than at baseline (76.6%). The experience registry – the 2 year, multi-center, non-interventional study of 916 patients also demonstrated that add-on therapy with Omalizumab was associated with a reduction(32.9 % in week 52) in the use of OCS and rescue therapy.

In the ACT (4) five questions must be answered and between 1 and 5 points are assigned per answer. There is thus a maximum score of 25. The definition established by the European Respiratory Society and the American Thoracic Society in 2014 defines severe asthma as a score under 20 during high-dose ICS (inhaled corticosteroid) therapy with an additional controller or during oral corticosteroid therapy for more than 6 months per year. Improvements were seen ACT scores at week 16 (score 17.1 vs. 11.3 at baseline) and week 52 (20.8 vs 11.3 at baseline). The retrospective APEX (Asthma Patient Experience on Xolair) study in clinical practice in the UK (n=136) shows improvement in ACT Score at week 52 (20 vs 11 at baseline).
In experience registry there was improvements in ACT Score at week 52 (19.1 vs 13 at baseline).

**Rescue medication use:** Use of rescue medications decreased by 7.90 puffs (p <0.001) at 16 weeks and by 13.67 puffs (p <0.001) at 52 weeks from baseline. In experience registry there was improvements in rescue medication use (54.1 vs 87% patients at baseline). In the study by Holgate et al. the use of rescue medicine was reduced from baseline significantly more with omalizumab than placebo, and differences were significant from week 8 to study end (p ≤ 0.05 to <0.001).

**Lung function:** Lung function was improved significantly compared to baseline (change in FEV1 = 700 ml) at 52 weeks.

In INNOVATE Study the FEV1 (% predicted) was significantly improved with Omalizumab as compared to placebo at week 28 with a difference of 2.8% predicted in favour of Omalizumab. Improvements in FEV1 were 190 ml and 96 ml in the omalizumab and placebo groups, respectively.

**Table 3: Other parameters:** The change in ICS dose and LABA dose are shown in below table:

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Mean change from Baseline at 16 weeks</th>
<th>Mean change from Baseline at 52 weeks</th>
</tr>
</thead>
<tbody>
<tr>
<td>ICS dose</td>
<td>-287.50 mg (p&lt;.001)</td>
<td>-458.33 mg (p&lt;.05)</td>
</tr>
<tr>
<td>LABA dose</td>
<td>-26.25 (p&lt;.001)</td>
<td>-58.33 (p&lt;.001)</td>
</tr>
</tbody>
</table>

**Discussion**

A Cochrane review published in 2006 by Walker S, Monteil M, Phelan K, Lasserson T, Walters E of 14 randomized controlled trials in 3143 children and adults with mild to severe allergic asthma found that treatment with omalizumab reduced asthma exacerbations (OR 0.52, 95% CI, 0.41 to 0.65) and increased the proportion of patients who were able to reduce or withdraw inhaled corticosteroids [8]. In our study there were also reduced asthma exacerbations as shown in ACT scores - week 16 (score 17.1 vs. 11.3 at baseline) and week 52 (20.8 vs 11.3 at baseline).

A systematic review published in 2011 by Rodrigo GJ, Neffen H, Castro-Rodriguez J. of 8 randomized controlled trials in 3,429 children and adults with moderate to severe allergic asthma taking inhaled corticosteroids, including two trials published after 2006 [10,11] concluded that omalizumab treatment resulted in a higher proportion of subjects stepping-down and stopping inhaled corticosteroids (Relative risk [RR] = 1.80; 95% CI, 1.42–2.28) and reduced the risk of asthma exacerbations (RR = 0.57; 95% CI, 0.48–0.66) [9]. Similarly, in our study use of rescue medications decreased by 7.90 puffs (p <0.001) at 16 weeks and by 13.67 puffs (p <0.001) at 52 weeks from baseline.

Data from the systematic review published in 2011 suggested that the number needed to treat for benefit (NTTB) in reducing the rate of exacerbations was 10. A post-hoc analysis suggested that the beneficial effects of omalizumab were not dependent on the age, duration of treatment, or disease severity. A study included in the systematic review that provided evidence for the efficacy of omalizumab in children was a 52 week randomized placebo-controlled trial in 627 children aged 6 to <12 years with perennial allergen asthma and a history of exacerbations and poor symptom treatment with medium-dose or high-dose inhaled corticosteroids with or without other controller medications.

Omalizumab treatment reduced asthma exacerbations by 31% compared to placebo during the first 24-weeks of the study, when the inhaled corticosteroid dose remained stable, and by 43% over a period of 52 weeks, which included a 28-week adjustable-corticosteroid phase. In this study the secondary outcomes including symptoms, reliever bronchodilator use and reduction in inhaled corticosteroid dose were not significantly improved by omalizumab treatment [9,10].

Recent publications by Ohta K, Miyamoto T, Amagasaki T, Yamamoto M and Hanania NA, Alpan O, Hamilos DL, Condemi JJ, Reyes-Rivera I, Zhu J, et al have provided important new information on the use of omalizumab as an add-on treatment to high dose inhaled corticosteroids and inhaled long-acting β2 agonist bronchodilators in severe allergic asthma and in children and young adults with allergic asthma [11,12].

A randomized controlled trial in 850 patients who had inadequately controlled asthma despite treatment with high dose inhaled corticosteroids (≥500 mcg of fluticasone inhaler twice daily or equivalent) and inhaled long-acting β2 agonist bronchodilators, with or without other controllers assessed the benefits of the addition of omalizumab over a 48 week period [11]. At the end of the treatment period omalizumab produced a 25% relative reduction in the rate of asthma exacerbations.
Our study also demonstrates clinical benefits obtained from the addition of omalizumab to patients with poorly controlled severe allergic asthma despite treatment with high dose inhaled corticosteroids and inhaled long-acting β2 agonist bronchodilators, although the magnitude of benefit is relatively small.

Interestingly there was a large placebo effect observed in the control group, a finding which has been noted in previous studies with omalizumab. At baseline, seventeen percent of participants were receiving either chronic oral corticosteroids or an oral corticosteroid course at least 4 times per year, and in this sub-group there was no clinical benefit although it should be noted that the study was not powered to detect a treatment effect [12,13].

Several observational studies have reported on ‘real life’ experience with omalizumab in treating patients with allergic asthma in France [15], Germany [16], Belgium [17], United Kingdom [18], Italy [19], South-Eastern Mediterranean centers [20], Israel [21], Spain [22] and other countries. Taken together, the results of these studies suggest that omalizumab is an effective treatment for patients with poorly controlled allergic asthma and that is comparable to our study. Our findings are in agreement with those of other studies of omalizumab in various parts of the world, a brief account of which is compared below [8-23]:

**Summary and Conclusion:** In this study, omalizumab was associated with a reduction in maintenance OCS use in patients with uncontrolled persistent allergic asthma. The mean daily requirement of OCS, as well as the number of patients on OCS – both have been reduced significantly with omalizumab treatment for 52 weeks.

The use of OCS is associated with serious long-term adverse effects such as hypothalamic-pituitary-adrenal axis suppression, impaired glucose tolerance and diabetes, osteoporosis, hypertension, and cataract formation. Therefore, a therapy that improve outcomes, have acceptable safety and tolerability profiles, while allowing reductions in OCS use is really helpful for the patients.

In addition of reduction in OCS use, patients enrolled in the study also experienced an significantly improved lung function and a significant reduction in daily rescue medication use. These two parameters are very closely related to patients’ overall quality of life.

Although measurement of QoL was in the scope of this study, it is expected to improve significantly – as implied from the other parameters [7].

The maintenance dose of ICS and LABA were also reduced significantly in this study, which suggested an improvement in asthma control. This is further demonstrated by the status of asthma severity analysis, which showed after 52 weeks, no patients were classified as ‘severe’ asthmatics.

So to conclude, it can be said that Omalizumab is a recombinant humanized monoclonal antibody that binds circulating IgE antibody.

It is approved in the US and Europe, as well as many other countries, for the treatment of adults and adolescents aged 12 years and above with moderate to severe persistent allergic asthma, whose symptoms are poorly controlled with inhaled corticosteroids, plus in Europe patients should also be receiving inhaled long-acting β2 agonist bronchodilators.

In Europe, the licence also includes children aged 6 to <12 years as an add-on treatment for poorly controlled asthma in patients with severe persistent allergic asthma.

**Limitations**
- Small no. of patients were included in this study.
- Because of high cost of the drug study could not be conducted in a large scale

**Contribution by authors**

1) **Dr. Saswata Gayen and Dr. Prosenjit Gayen:** Concept designed and conducting the study.

2) **Dr. Animesh Mandal:** Conducting study and writing manuscript.

3) **Prof. Ramtanu Bandyopadhyay:** Guiding the study procedure and preparing the manuscript suitable for publication.

**Reference**

DOI: 10.1111/j.1398-9995.2004.00772.x [Crossref]
Ghosh S. et al: Assessment of efficacy of Anti-IgE (Omalizumab)


06. Rodrigo GJ, et al. Systematic review on the use of omalizumab for the treatment of asthmatic children and adolescents. Paediatric Allergy and Immunol. 2015;26;551-6. [Crossref]


08. Walker S, Monteil M, Phelan K, Lasserson T, Walters E. Anti-IgE for chronic asthma in adults and children. Cochrane Database of Systematic Reviews. 2006;2;CD003559. doi: 10.1002/14651858.CD003559.pub3 [Crossref]


